Kura (KURA) Revenue Drops 61%
Kura Oncology (NASDAQ:KURA), a clinical-stage company specializing in precision cancer medicines, released its second quarter 2025 financial results on August 7, 2025. The headline news was a sharp miss on collaboration revenue, with $15.3 million (GAAP) reported versus analyst expectations of $39.1 million. As there are still no product sales, all revenue in the period reflected payments under partnership agreements. Operating expenses in R&D and administration rose significantly from the prior year, widening the net loss to $66.1 million (GAAP). While Kura continued clinical and regulatory momentum with its lead asset ziftomenib, the quarter highlights mounting financial pressure as the company ramps toward potential commercial operations.
Source: Analyst estimates for the quarter provided by FactSet.
Kura Oncology is focused on developing targeted therapies for genetically defined cancers. The company’s primary asset is ziftomenib, a menin inhibitor drug designed for genetically defined subtypes of leukemia such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Ziftomenib is being evaluated in the relapsed/refractory NPM1-mutant AML population, a group with limited current treatment options.
Source Fool.com
